Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Expect Approval of Qnexa by the PDUFA Date
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Price: $13.76 -1.78%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade VVUS Now!
Needham & Company reiterates a 'Buy' on Vivus (NASDAQ: VVUS) price target of $26.00.
Analyst, Alan Carr, said, "Vivus management hosted a quarterly conference call yesterday after market close. The Qnexa PDUFA date was moved last month from 4/17/12 to 7/17/12. We do not believe the extension adds greater risk to approval of Qnexa. Rather, we believe this is simply a matter of the FDA requiring more time to review the submission. Management announced last night that the company is discussing REMS materials and the Qnexa label with the FDA. The agency is also reportedly reviewing proposed Phase 4 CV trial design. We expect approval of Qnexa by the PDUFA date and reiterate our rating."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $23.58 yesterday, with a 52 week range of $6.13-$26.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Alan Carr, said, "Vivus management hosted a quarterly conference call yesterday after market close. The Qnexa PDUFA date was moved last month from 4/17/12 to 7/17/12. We do not believe the extension adds greater risk to approval of Qnexa. Rather, we believe this is simply a matter of the FDA requiring more time to review the submission. Management announced last night that the company is discussing REMS materials and the Qnexa label with the FDA. The agency is also reportedly reviewing proposed Phase 4 CV trial design. We expect approval of Qnexa by the PDUFA date and reiterate our rating."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $23.58 yesterday, with a 52 week range of $6.13-$26.75.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- VIVUS (VVUS) Qsymia Prescriptions Fall Ahead of Belviq Launch (ARNA)
- KeyBanc Downgrades Sanderson Farms (SAFM) to Hold
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Needham & Company, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
